Cohance Lifesciences Analyst Review May 2026

This Cohance Lifesciences analyst review for May 2026 covers the key data investors need for COHANCE at its current price of Rs 416.90. Cohance Lifesciences (NSE: COHANCE) is a pharmaceutical CDMO company with a market capitalisation of approximately Rs 10,000 crore, specialising in APIs and custom synthesis for regulated markets. The analyst consensus target of Rs 500 implies meaningful upside, and this Cohance Lifesciences analyst review examines technical levels, business performance, valuation, and key risks that will determine whether COHANCE achieves that target through FY27.

Click Here – Get Free Investment Predictions

Cohance Lifesciences Company Snapshot May 2026

Cohance (formerly Suven Pharmaceuticals after the Advent International acquisition and restructuring) focuses on high-value CDMO services for global innovator pharma companies including neuroscience and metabolic disease molecules. The table below summarises the key data referenced in this Cohance Lifesciences analyst review.

Parameter	Value
NSE Ticker	COHANCE
Sector	Pharmaceuticals – CDMO
CMP (May 2026)	Rs 416.90
52 Week High	Rs 1,121.15
52 Week Low	Rs 266.70
Market Cap	Rs 10,000 Crore
Trailing P/E	30x
Analyst Consensus Target	Rs 500
Bull Case Target	Rs 620
Bear Case Target	Rs 340

Analyst Insight in This Cohance Lifesciences Analyst Review

Senior Research Analyst Ankit Jaiswal flags Cohance Lifesciences as a stock to watch in May 2026. At Rs 416.90, Ankit Jaiswal identifies key support in the Rs 272 to Rs 396 band and resistance near Rs 442. He suggests watching Cohance Lifesciences for a potential move toward Rs 500, subject to Pharmaceuticals – CDMO sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Cohance Lifesciences analyst review and does not constitute a trade recommendation.

Technical Analysis in This Cohance Lifesciences Analyst Review

At Rs 416.90, COHANCE is trading within its 52-week band of Rs 266.70 to Rs 1,121.15. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 272 to Rs 396 band while resistance is seen in the Rs 442 to Rs 458 zone. A sustained move above Rs 442 could open the path toward the analyst consensus target of Rs 500.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 272 to Rs 396 – investors tracking this Cohance Lifesciences analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for COHANCE.
• Resistance Zone: Rs 442 to Rs 458 – a sustained close above Rs 442 would be a positive breakout signal worth flagging in this Cohance Lifesciences analyst review.
• Medium-Term Target: The analyst consensus of Rs 500 represents the base-case upside scenario identified in this Cohance Lifesciences analyst review.

Business Segment Analysis

API Custom Synthesis for Global Pharma Innovators

This is the primary revenue and margin driver for Cohance Lifesciences, directly supporting the earnings trajectory toward the consensus target of Rs 500.

Generic API Manufacturing

This segment adds scale and diversification to Cohance Lifesciences’s business model and is a meaningful EPS contributor through FY27 and FY28.

Formulation Development and Clinical Manufacturing

This represents the medium-term growth frontier for Cohance Lifesciences and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Cohance Lifesciences Analyst Review

At Rs 416.90, Cohance Lifesciences trades at a trailing P/E of 30x. This Cohance Lifesciences analyst review presents three valuation scenarios: a bull case of Rs 620 on strong earnings delivery and sector tailwinds, a base case of Rs 500 at analyst consensus, and a bear case of Rs 340 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Cohance Lifesciences analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 620	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 500	Moderate growth, analyst consensus estimate
Bear Case	Rs 340	Earnings miss or macro headwinds

Trade Outlook for Cohance Lifesciences

Based on the technical and fundamental analysis in this Cohance Lifesciences analyst review, investors might watch COHANCE near the support zone of Rs 272 to Rs 396 for potential opportunities. A flag above Rs 442 could suggest improving momentum toward Rs 500. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Cohance Lifesciences in FY27

A well-rounded Cohance Lifesciences analyst review must assess downside risks. Key risks for Cohance Lifesciences include a macro slowdown affecting Pharmaceuticals – CDMO sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in COHANCE.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Cohance Lifesciences Analyst Review Verdict for 2026

This Cohance Lifesciences analyst review concludes that at Rs 416.90, COHANCE offers a defined risk-reward with a consensus target of Rs 500. The 52-week range of Rs 266.70 to Rs 1,121.15 provides context on the current entry point. Use this Cohance Lifesciences analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on COHANCE.

Frequently Asked Questions: Cohance Lifesciences Analyst Review 2026

What is the analyst target for Cohance Lifesciences in 2026?

The analyst consensus target is Rs 500, with a bull case of Rs 620 and a bear case of Rs 340. Monitor Q1 FY27 earnings for confirmation as highlighted in this Cohance Lifesciences analyst review.

Is Cohance Lifesciences a good investment at Rs 416.90?

At Rs 416.90 with a P/E of 30x and a consensus target of Rs 500, this Cohance Lifesciences analyst review is constructive for medium to long-term investors in the Pharmaceuticals – CDMO sector. Always consult a SEBI-registered advisor before investing.

What is Cohance Lifesciences’s 52-week high and low?

The 52-week high is Rs 1,121.15 and the 52-week low is Rs 266.70. At Rs 416.90, COHANCE is positioned within this range as noted in this Cohance Lifesciences analyst review.

What are the key risks for Cohance Lifesciences?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – CDMO sector as assessed in this Cohance Lifesciences analyst review.

Where can I track live data for Cohance Lifesciences?

Track Cohance Lifesciences’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Cohance Lifesciences analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.